evipedia.ai
← Back

DHEA for Health & Longevity

Evidence Review created on 09/09/2026 using AI4L / Opus 5

Also known as: Dehydroepiandrosterone, Prasterone, Androstenolone, DHEA-S, Dehydroepiandrosterone Sulfate, 3β-hydroxyandrost-5-en-17-one

Motivation

DHEA (dehydroepiandrosterone) is a hormone made mainly by the adrenal glands, two small organs that sit on top of the kidneys. The body treats it as raw material, converting it inside tissues into the male and female sex hormones, and it also acts on some tissues directly. Its blood level peaks in a person’s twenties and then falls year after year, so that by the seventies only a small fraction of the youthful amount is left.

That steep and unusually predictable decline made the hormone one of the first substances marketed for slowing the effects of age. It has been sold over the counter in the United States since 1994 and remains a prescription medicine across much of Europe. Interest has been sustained by a simple observation: the people with the lowest levels tend to be the frailest and to die soonest.

This review examines the controlled human research on taking DHEA — which effects hold up and which do not, how swallowing it differs from applying it locally, what the safety record looks like over months to years, and where the evidence remains thin.

Benefits - Risks - Protocol - Conclusion

High-level overviews of DHEA from expert commentators and narrative reviews that frame the hormone’s role in aging.

Note on priority sources: dedicated DHEA content could not be found from Rhonda Patrick or Chris Kresser. On-site searches returned only passing mentions — DHEA-S (dehydroepiandrosterone sulfate, the long-lived storage form measured in blood) named as a biomarker inside broader episodes and articles on protein, alcohol, adrenal fatigue and thyroid function — none of which discusses DHEA itself in enough depth to qualify.

Grokipedia

  • Dehydroepiandrosterone

    A structural and physiological reference entry covering biosynthesis in the zona reticularis, the sulfated circulating form, and the age-related decline curve.

Examine

  • DHEA

    Grades DHEA across nineteen conditions from 1,903 participants, and carries a safety database covering androgenic side effects, hormone-sensitive cancer precautions, soy and anticoagulant interactions, and doping status.

ConsumerLab

  • DHEA Supplements Review

    Independent assay results for six DHEA products purchased in 2026, with per-milligram cost comparisons spanning a twelve-fold range and a summary of which claimed benefits survive scrutiny.

Systematic Reviews

The pooled evidence on DHEA’s benefits and its principal metabolic harm.

Mechanism of Action

DHEA is synthesised in the zona reticularis (the innermost layer of the adrenal cortex) from cholesterol via pregnenolone, with CYP17A1 (the enzyme that adds and then cleaves a side chain to make androgens) performing the final step. Most of it circulates as the sulfated storage form DHEA-S, created by SULT2A1 (the enzyme that attaches a sulfate group) and reactivated in tissues by steroid sulfatase (the enzyme that strips that sulfate off again).

DHEA has no high-affinity receptor of its own. It acts chiefly as a prohormone through intracrinology: target tissues import it and convert it locally using 3β-HSD and 17β-HSD (enzymes that build androstenedione and then testosterone) and CYP19A1 aromatase (the enzyme that turns androgens into estrogens). This is why the same dose raises testosterone more in women and estrogen more in men — the tissue, not the capsule, decides.

Proposed direct actions include negative modulation of the GABA-A receptor and positive modulation of the NMDA receptor (the brain’s main calming and excitatory switches), activation of PPAR-α (a fat-burning gene switch), and inhibition of G6PD (glucose-6-phosphate dehydrogenase, an enzyme feeding fat synthesis). Critics counter that these occur only at concentrations far above those reached in humans, and that every reproducible human effect is downstream sex-steroid action.

Pharmacologically, DHEA is non-selective, distributes widely into brain, skin, adipose and gonadal tissue, and has a plasma half-life of roughly 15–30 minutes; DHEA-S persists 7–10 hours. Oral bioavailability is low because of rapid first-pass sulfation in gut and liver.

Historical Context & Evolution

DHEA was first isolated from male urine by Adolf Butenandt’s Berlin laboratory in 1934 and remained a curiosity of steroid chemistry for two decades. By the late 1950s researchers had shown that its blood concentration falls steeply with age — the first finding that tied it to aging rather than to reproduction.

Interest turned practical in the 1980s, when rodent work reported that feeding DHEA to mice reduced tumour formation, body fat and diabetes. Those findings were real and reproducible in that species, but rodent adrenal glands make essentially no DHEA of their own, so the doses used were pharmacological rather than replacement. In 1986 a prospective cohort in Rancho Bernardo found that men with higher DHEA-S levels died less often of heart disease, which moved the hypothesis into humans.

Regulation then shaped the field more than science did. The FDA (U.S. Food and Drug Administration) removed DHEA from over-the-counter sale in 1985 for want of proof of benefit; the Dietary Supplement Health and Education Act of 1994 returned it as a supplement, after which sales grew quickly and marketing outran the data.

The trials that followed split the picture rather than closing it. Replacement in adrenal failure and local vaginal use held up; general longevity use in healthy older adults did not. The 2016 approval of an intravaginal preparation for painful intercourse remains the only regulator-endorsed indication. The rodent work was never refuted — it simply did not transfer to a species whose adrenal glands already make the hormone.

Expected Benefits

High 🟩 🟩 🟩

Reversal of Vulvovaginal Atrophy and Painful Intercourse

Applied inside the vagina, DHEA is converted locally into estrogen and testosterone by the tissue itself, restoring cell maturation, lowering vaginal pH and easing dryness and pain during intercourse (dyspareunia). A 2026 meta-analysis of five RCTs (randomized controlled trials, in which participants are assigned by chance to treatment or placebo) in 1,611 postmenopausal women found consistent benefit with mild, infrequent adverse effects. Most of those trials were funded by EndoCeutics, the manufacturer that developed the prescription product — a financial interest shaping this entire evidence base.

Magnitude: Vaginal dryness improved by 0.23 points and painful intercourse by 0.40 points more than placebo on 0–3 severity scales.

Restored Well-Being in Adrenal Insufficiency

In people whose adrenal glands cannot make DHEA, replacement restores blood levels to the normal range and improves overall well-being, mood and sexual interest. A meta-analysis of ten placebo-controlled trials in women with this condition found a small but consistent gain on validated quality-of-life scales, and the landmark 1999 crossover trial found parallel improvements in depression and anxiety scores. This is correction of a true deficiency rather than a boost above normal, which is why it does not generalise to people with working adrenal glands.

Magnitude: Effect size 0.21 (95% CI 0.08 to 0.33; CI is the confidence interval, the range within which the true effect most likely lies) for health-related quality of life across ten trials.

Reduced Depressive Symptoms

Across trials in depressed, medically ill and healthy participants, oral DHEA lowered depression-rating scores more than placebo, plausibly through neurosteroid actions at the brain receptors described in Mechanism of Action. The pooled estimate came from 12 trials in 742 people with low heterogeneity (the trials agreed closely with one another), but the authors rated their own certainty as very low because the component trials were small and at risk of bias. Reported side effects were uncommon, mild and androgenic in character.

Magnitude: Standardized mean difference −0.28 (95% CI −0.45 to −0.11), a small effect of roughly a quarter of a standard deviation on depression scales.

Improved Self-Rated Health in Systemic Lupus Erythematosus

In systemic lupus erythematosus (a long-term disease in which the immune system attacks the body’s own tissues), oral DHEA raises how patients rate their own health and lets some cut their steroid dose, plausibly by restoring an androgen-to-cortisol balance that the disease depresses. A Cochrane review of seven placebo-controlled trials in 842 participants graded that quality-of-life gain as modest but clinically meaningful, while formal disease-activity scores shifted in only one of the six trials reporting them. Acne roughly doubled.

Magnitude: Patient global assessment of health improved 11.5 points more than placebo on a 0–100 scale across the pooled trials.

Medium 🟩 🟩

Reduced Arterial Stiffness

Arterial stiffness rises with age and independently predicts cardiovascular events. In a randomized, double-blind trial in 92 adults aged 65 to 75, 50 mg daily reduced the carotid augmentation index — a validated measure of how much reflected pressure waves load the heart — alongside falls in two inflammatory signalling proteins. The finding rests on a single trial from one research group, has not been replicated, and the companion measure of pulse-wave velocity lost significance after adjustment for baseline values.

Magnitude: Carotid augmentation index fell 6 ± 2 units more than placebo; pulse-wave velocity fell 3.5 ± 1.0 m/s but was not significant after adjustment.

Low 🟩

Increased Bone Mineral Density in Women ⚠️ Conflicted

Two-year supplementation raised spinal BMD (bone mineral density, the standard measure of skeletal strength) in older women but not men, and a meta-analysis found hip gains in women only. A separate pooled analysis found no effect. The sex split most likely explains the discrepancy: on balance, a small female-only benefit.

Magnitude: Lumbar spine density rose 1.7% at one year and 3.6% at two years in women; men showed no change at any site.

Reduced Visceral Fat and Improved Insulin Action ⚠️ Conflicted

A six-month trial in 56 older adults cut deep abdominal fat and improved an insulin-sensitivity index, while a two-year trial found no change in insulin sensitivity and a pooled analysis found lower fasting glucose but unchanged insulin resistance. Net reading: a small, inconsistent metabolic effect.

Magnitude: Visceral fat fell 13 cm² against a 3 cm² gain on placebo; pooled fasting glucose fell 2.19 mg/dL.

Improved Sexual Function in Women with Normal Adrenal Function ⚠️ Conflicted

A systematic review of 38 clinical studies reported gains in interest, arousal, lubrication and orgasm, strongest where dysfunction already existed. A meta-analysis restricted to postmenopausal women found no significant effect. Net reading: benefit appears confined to women who start with a problem.

Magnitude: The pooled estimate in postmenopausal women was a standardized mean difference of 0.35 (95% CI −0.02 to 0.73), which did not reach significance.

Muscle Strength and Physical Function in Older Adults ⚠️ Conflicted

A systematic review of eight trials in 661 adults over 50 found isolated gains in grip, chest press, leg press and knee extension, matched by an equal number of null results, and a two-year trial found no change in strength or aerobic capacity. Net reading: no reliable effect.

Magnitude: Direction is null on balance — scattered single-endpoint gains appear only in some trials and are offset by an equal number of null findings; the literature reports no pooled outcome figure.

Improved Skin Hydration and Sebum Production

A one-year placebo-controlled trial in 280 adults aged 60 to 79 reported better skin hydration, greater epidermal thickness, increased sebum production and improved pigmentation, most clearly in women. These were secondary endpoints and no independent trial has re-measured them.

Magnitude: After one year at 50 mg daily, active sebaceous gland spots rose from a median of 61 on placebo to 101 (P = 0.0008; P is the probability a difference this large would arise by chance) and forearm hydration from 71 to 86 arbitrary units (P = 0.01); in women over 70 sebum spots rose from 8.7 to 52.4 (P = 0.0001).

Improved Pregnancy Outcomes in Fertility Treatment ⚠️ Conflicted

Six pooled trials in 745 women with a low remaining egg supply report higher clinical pregnancy and live birth after DHEA, and a network meta-analysis agrees, but a stricter 2025 synthesis found only more eggs collected. Net reading: a probable gain in egg yield, with the live-birth benefit unconfirmed.

Magnitude: Clinical pregnancy odds were 1.45 times higher (95% CI 1.04 to 2.03) and live birth 2.70 times higher (1.24 to 5.85); the stricter pooled analysis found 0.6 more eggs collected and no live-birth gain.

Speculative 🟨

Thymic Regeneration and Reversal of Epigenetic Age

In an uncontrolled nine-man trial, DHEA was given with growth hormone and metformin; thymus tissue regrew and DNA-based age estimates fell. No design element isolates DHEA’s own contribution.

Immune Cell Restoration

A narrative review reports rises in monocytes, gamma-delta T cells and natural killer cells in older adults. These counts are unvalidated markers, not measured infection or immunity outcomes.

Benefit-Modifying Factors

  • SULT2A1 and CYP19A1 variants: Common variants in the sulfating enzyme and in aromatase (which converts androgens to estrogens) shift how much of a dose becomes testosterone versus estrogen, and genome-wide studies link SULT2A1 variants to circulating DHEA-S levels.

  • Baseline DHEA-S level: The clearest single modifier. Benefit concentrates where a true deficit exists; in older adults with age-related decline, a two-year placebo-controlled trial reported null results for muscle strength, physical performance and quality of life.

  • Sex: Women convert DHEA preferentially to testosterone and show the bone, mood and sexual-function signals; men convert preferentially to estrogen and show almost none of the bone or body-composition effects.

  • Adrenal insufficiency and hypopituitarism (a failing pituitary gland): Where the adrenal glands genuinely cannot produce DHEA, replacement behaves like true hormone replacement rather than supplementation, and the well-being effect is several times larger.

  • Menopausal status and vaginal tissue state: The local vaginal benefit requires atrophic tissue to act on; women without atrophy have no measurable endpoint to improve, which flattens the apparent effect.

  • Age at the older end: Adults over 70 have the steepest deficit and show the largest estradiol response and the bone signal, but also the thinnest safety data beyond two years.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Androgenic Skin and Hair Effects

Acne, oily skin and unwanted coarse hair growth (hirsutism) are the most frequently reported adverse effects, driven by conversion of DHEA into testosterone and DHT (dihydrotestosterone, the most potent androgen) inside skin and hair follicles. They recur across trials at 50 to 200 mg daily, are commoner in women, emerge within weeks, and reverse when the dose is reduced or stopped. Pooled trial data characterise them as mild and transient; menstrual irregularity, scalp hair thinning and voice deepening appear far less often and mainly at higher doses.

Magnitude: Acne risk roughly doubled against placebo in the pooled lupus trials (relative risk 2.2, 95% CI 1.65 to 2.83), with incidence rising across the 50–200 mg range and concentrating in women.

Reduction in High-Density Lipoprotein (HDL) Cholesterol

Oral DHEA lowers HDL (the particle that carries cholesterol away from artery walls), an effect shared with other androgens and generally attributed to increased activity of hepatic lipase (the liver enzyme that breaks those particles down). A meta-analysis of 23 randomized trials found the fall confined to women, with no change in total cholesterol, low-density lipoprotein or triglycerides. Whether a shift this size translates into cardiovascular events has never been tested, and the same agent improves arterial stiffness.

Magnitude: HDL cholesterol fell 3.1 mg/dL overall (95% CI −4.9 to −1.3) and 5.1 mg/dL in women; men showed no change.

Application-Site Discharge with the Intravaginal Route

The leading adverse event in intravaginal DHEA trials is discharge at the application site, produced by the melting fat base of the insert rather than by the hormone. It is mild, rarely prompts discontinuation, and the 2026 pooled analysis found no major safety concerns across 1,611 women. Systemic hormone exposure from this route stays inside the postmenopausal reference range.

Magnitude: Discharge occurs more often than with placebo and is concentrated in the first weeks of use as the insert base dissolves; the pooled analysis reports no combined incidence figure.

Medium 🟥 🟥

No risk sits at Medium: every remaining adverse effect is either a documented event replicated across controlled trials, or rests on hormone-level shifts, uncontrolled case reports and cell-culture work rather than a measured harm in one controlled trial.

Low 🟥

Unintended Rise in Estradiol and Testosterone

A meta-analysis of 21 trial arms in 1,223 women found estradiol rose predictably at 50 mg daily, most in women over 60, and a companion analysis found testosterone rose in older women. The harm is inferred from these shifts rather than measured, so the clinical consequence stays unquantified.

Magnitude: Estradiol rose 7.02 pg/mL on average (95% CI 5.43 to 8.62); testosterone rose 17.52 ng/dL in older women.

Disturbed Glucose Handling ⚠️ Conflicted

Consumer testing bodies flag possible insulin resistance, yet a dose-response meta-analysis of 14 trials found fasting glucose slightly lower and insulin resistance unchanged, and a two-year trial found no change in insulin sensitivity. Net reading: no consistent adverse glucose effect at 50 mg daily.

Magnitude: Fasting glucose fell 2.185 mg/dL overall; the HOMA-IR index (a calculation estimating insulin resistance from fasting glucose and insulin) shifted by 0.174, which was not significant.

Mood Activation, Irritability and Insomnia

Trial adverse-event tallies and case reports describe agitation, irritability and disturbed sleep, occasionally mania in people with bipolar disorder, consistent with the hormone’s excitatory receptor actions. These reports are uncontrolled, and the pooled depression trials recorded side effects as uncommon and transient.

Magnitude: Not quantified in available studies. No controlled trial has used activation or insomnia as a pre-specified outcome, so only case reports and volunteered adverse-event tallies exist.

Suppression of Circulating Cortisol

A meta-analysis of ten trial arms found DHEA lowered blood cortisol, probably through feedback on ACTH (adrenocorticotropic hormone, the pituitary signal that drives the adrenal glands). Whether this matters clinically is untested; the same authors framed it as a possible benefit in excess-cortisol states.

Magnitude: Cortisol fell 53.581 nmol/L (95% CI −88.2 to −18.9); liver enzymes were unchanged in the same analysis.

Stimulation of Hormone-Sensitive Cancers

Cell-culture work shows DHEA stimulates prostate cancer cell growth and PSA (prostate-specific antigen, a blood marker of prostate activity) output, and cohort data link higher pre-diagnosis DHEA-S to postmenopausal breast cancer. No supplementation trial has measured cancer incidence, so the human evidence is observational.

Magnitude: Postmenopausal women in the top third for both DHEA-S and breast density had 3.5 times the odds of breast cancer (95% CI 1.9 to 6.3) of those in the bottom third.

Speculative 🟨

Increased Bleeding Risk Alongside Anticoagulants

A small human study found that DHEA inhibits platelet clumping, raising a theoretical additive effect with anticoagulant medication. No study has reported an actual bleeding event attributable to DHEA.

Palpitations and Irregular Heartbeat

A published case report links DHEA use to a disturbed heart rhythm, and drug references list palpitations. No controlled trial has measured cardiac rhythm, so the basis is isolated reports.

Risk-Modifying Factors

  • CYP19A1 aromatase activity: Higher aromatase activity, whether genetic or driven by visceral fat, diverts more of the dose to estrogen, raising breast-tenderness and fluid-retention risk in men and estrogen exposure in women.

  • Baseline HDL and DHEA-S: Women who start with borderline HDL absorb the whole of the cholesterol hit; people already inside the youthful DHEA-S range gain nothing to offset it.

  • Sex: Women carry nearly all the androgenic and HDL risk; men carry the estrogen-excess and prostate-stimulation concerns. The same 50 mg dose is not equivalent across sexes.

  • Hormone-sensitive disease: Breast, endometrial, ovarian and prostate cancer, and a personal history of any of them, convert a theoretical proliferation signal into an unacceptable one.

  • Age at the older end: Adults over 60 show the largest estradiol rise per milligram and the least reserve for androgenic skin changes, while safety data past two years are essentially absent.

  • Liver and kidney function: Impairment slows sulfation and clearance, raising exposure from a nominal dose, though pooled trials found no change in liver enzymes at conventional doses.

Key Interactions & Contraindications

  • Anti-estrogens (drugs that block or lower estrogen: tamoxifen, fulvestrant, and the aromatase inhibitors anastrozole, letrozole, exemestane): Absolute contraindication. DHEA raises the estrogens these drugs are prescribed to suppress, undermining the treatment. No mitigation exists; the combination is avoided.

  • Anticoagulants and antiplatelet drugs (blood thinners: warfarin, apixaban, clopidogrel, aspirin): Caution. DHEA reduces platelet clumping in a small human trial, a theoretically additive bleeding risk. Mitigation: no stacking of other platelet-active supplements, with unusual bruising reported promptly.

  • Insulin and sulfonylureas (drugs that make the pancreas release more insulin: glipizide, glimepiride): Monitor. Pooled trials show a small fall in fasting glucose, compounding glucose-lowering medication. Mitigation: fasting glucose checked at 4 and 12 weeks.

  • Corticosteroids (anti-inflammatory steroid drugs: prednisone, hydrocortisone, dexamethasone): Caution. Chronic steroid use suppresses adrenal DHEA output, so a standard dose can overshoot. Mitigation: DHEA-S measured first, with a 10–15 mg start.

  • CYP3A4 inhibitors (blockers of the main liver drug-clearing enzyme: ketoconazole, ritonavir, clarithromycin, grapefruit juice): Monitor. These slow clearance of DHEA metabolites, raising androgen and estrogen exposure. Mitigation: a reduced dose, with hormone panels rechecked after four weeks.

  • Over-the-counter medications — cimetidine, high-dose ibuprofen or naproxen: Monitor. Cimetidine has weak anti-androgen activity that blunts the effect; the anti-inflammatory drugs add to the platelet effect. Mitigation: separated dosing times and limited chronic use.

  • Supplement interactions — soy isoflavones: Monitor. A randomized crossover trial found a high-isoflavone diet lowered circulating DHEA-S, which can mask or offset supplementation. Mitigation: soy intake held steady across testing periods.

  • Additive androgen and estrogen supplements — pregnenolone, 7-keto-DHEA, Tribulus, boron, testosterone or estrogen therapy: Caution. These act on the same steroid pathway and stack unpredictably. Mitigation: one hormonal agent changed at a time, with retesting before the next.

  • Other interventions — resistance training and sauna: Additive rather than adverse. Both raise endogenous androgens acutely, so an unmonitored combination can push levels above target. Mitigation: testing after training blocks rather than during deloads.

Populations who should avoid DHEA:

  • Anyone with current or previous hormone-sensitive cancer — breast, endometrial, ovarian or prostate — including prostate cancer under active surveillance or a PSA above 4 ng/mL
  • Men with untreated benign prostatic hyperplasia (an enlarged prostate) and an International Prostate Symptom Score above 19
  • Women who are pregnant or breastfeeding, on the grounds that safety has never been established and androgen exposure to the fetus is plausible
  • Anyone under 30 with normal adrenal function, in whom DHEA-S is already at its lifetime peak
  • People with bipolar disorder, given repeated reports of activation and mania
  • Competitive athletes governed by anti-doping rules, for whom DHEA is prohibited at all times
  • People with severe hepatic impairment (Child-Pugh Class C, the most advanced grade of liver failure)

Risk Mitigation Strategies

  • Testing before treating: DHEA-S is measured first, and supplementation proceeds only below the youthful range. This prevents the overshoot that drives androgenic skin effects and estradiol excess in people who never had a deficit.

  • Low starting dose with laboratory-guided titration: Protocols typically begin at 10–15 mg daily in women and 25 mg in men, retest DHEA-S at 6–8 weeks, and adjust in 5–10 mg steps, limiting dose-driven acne and hirsutism.

  • Early lipid tracking: A fasting lipid panel at baseline and again at 3 months captures the HDL fall, which appears early. A drop below 50 mg/dL in women is the usual signal to reduce or stop.

  • Sex-specific hormone monitoring: Estradiol in men and testosterone in women, retested at 8–12 weeks, catches the conversion imbalance producing breast tenderness in men and hair or voice changes in women before it becomes visible.

  • Prostate screening before starting in men over 40: Baseline PSA and digital examination, repeated annually, guard against the androgen rise unmasking occult prostate disease.

  • Lowest effective dose, with route matched to the target: Vaginal atrophy responds to intravaginal DHEA without meaningful systemic hormone exposure, avoiding the cholesterol and androgenic effects entirely.

  • Morning dosing: Dosing on waking mirrors the natural adrenal rhythm and limits the activation and insomnia reported with evening administration.

Therapeutic Protocol

  • Standard replacement dose: 25–50 mg orally each morning is the range used in almost every longevity trial. Practitioners aiming at replacement rather than pharmacology commonly use 10–25 mg in women and 25–50 mg in men.

  • Competing approach — laboratory-guided replacement: Life Extension, which sells DHEA, popularised titrating to DHEA-S targets of 275–400 µg/dL in women and 350–500 µg/dL in men. Its revenue depends on that recommendation.

  • Competing approach — deficiency-only prescribing: Endocrinology practice, exemplified by the Würzburg group behind the 1999 adrenal insufficiency trial, restricts DHEA to documented adrenal failure at a fixed 50 mg and does not treat age-related decline.

  • Competing approach — local intravaginal use: A 6.5 mg vaginal insert nightly, developed by EndoCeutics and approved in 2016, treats vulvovaginal atrophy without systemic exposure. The company funded the supporting trials.

  • Best time of day: Morning, on waking. This mirrors the adrenal secretion peak and limits the sleep disruption reported with evening dosing.

  • Half-life: DHEA itself clears in roughly 15–30 minutes; the sulfated form persists 7–10 hours, which is why a once-daily dose sustains levels.

  • Single versus split dosing: Once daily is standard and adequate given the sulfate reservoir. Splitting is used only above 50 mg, where it slightly blunts the peak androgen surge.

  • Genetic considerations: SULT2A1 variants alter how much circulates as the storage form; high-activity CYP19A1 genotypes shift more of the dose to estrogen; COMT variants (the enzyme clearing stress chemicals and estrogens) may amplify reported activation.

  • Sex-based differences: Women need roughly half the male dose for the same DHEA-S rise and convert preferentially to testosterone; men convert preferentially to estrogen. Dosing men and women identically is the commonest protocol error.

  • Age-related adjustment: Adults over 70 reach target on lower doses and show the largest estradiol response, so titration steps of 5 mg and an extra retest at 6 months are usual.

  • Baseline biomarkers that drive the protocol: DHEA-S determines whether to treat at all; HDL cholesterol and PSA determine the ceiling; baseline testosterone and estradiol determine the direction of conversion.

  • Pre-existing conditions: Polycystic ovary syndrome, chronic corticosteroid use, hypopituitarism and treated hypothyroidism each change the starting dose, and each warrants confirming adrenal status before beginning.

Discontinuation & Cycling

  • Intended duration: Framed as indefinite replacement rather than a course, since blood levels return to their untreated baseline within days of stopping. The absence of trials beyond two years is the practical limit on that framing.

  • Withdrawal effects: None described. Trials that stopped DHEA abruptly, including the year-long placebo-controlled studies, reported no rebound symptoms and no adrenal suppression, because DHEA does not meaningfully inhibit the pituitary signal.

  • Tapering: Not required pharmacologically. Where androgenic side effects prompt stopping, halving the dose for two weeks is used simply to confirm that the dose, not something else, caused them.

  • Cycling for efficacy: No evidence supports it. Receptor downregulation has not been demonstrated, and the sustained bone and skin effects were measured under continuous dosing for one to two years.

  • Cycling for safety: Some practitioners pause 4–8 weeks annually to re-measure untreated DHEA-S and confirm the deficit persists. This is a monitoring convention, not an efficacy strategy.

  • Stopping trigger: A confirmed HDL fall, a rising PSA, persistent acne or hirsutism, or a DHEA-S above the youthful range each ends the trial of therapy rather than prompting a dose reduction.

Sourcing and Quality

  • Third-party testing is the minimum filter: Independent 2026 assays of six DHEA products found labelled amounts accurate within a reasonable margin, but an earlier round found one brand at 14.7% of its stated dose. Certification from an independent laboratory closes that gap.

  • Capsule strength matched to the target dose: Labelled strengths span 5 mg to 25 mg. Stacking several low-dose capsules to reach a target can cost up to twelve times as much as one correctly sized product.

  • Cost per milligram varies enormously: The price of 25 mg ranged from 6 cents to 77 cents across tested products, with no relationship between price and assay accuracy.

  • Micronised formulation: Micronisation improves the absorption of a poorly soluble steroid and is the form used in most clinical trials, including the year-long European trial.

  • Brands that passed independent testing: Products from Life Extension, Pure Encapsulations, Douglas Laboratories, Designs for Health, Nutricost and Vitacost were among those assayed in 2026. Life Extension’s own magazine also promotes DHEA.

  • Compounding pharmacies for non-standard doses: Doses below 10 mg, and topical or vaginal preparations outside the approved product, generally require a compounding pharmacy operating under United States Pharmacopeia standards.

  • Combination “hormone support” blends: Products stacking DHEA with pregnenolone, 7-keto-DHEA or herbal androgen precursors make the achieved dose unknowable and defeat laboratory-guided titration, which is why single-ingredient products dominate trial protocols.

Practical Considerations

  • Time to effect: Blood levels normalise within days, but endpoints lag. Mood changes appear at 4–8 weeks, sexual-function and skin changes at 3–6 months, and bone density changes are not measurable before 12 months.

  • Common pitfall — treating without testing: The trials that failed largely enrolled adults with intact adrenal function rather than a documented deficiency. Supplementing without a baseline DHEA-S measurement accepts the whole risk profile with no prospect of the deficiency-replacement benefit.

  • Common pitfall — dosing men and women alike: The same 50 mg produces very different androgen and estrogen exposures by sex, and is the usual reason for unexpected acne in women or breast tenderness in men.

  • Common pitfall — expecting strength or memory gains: Both have been tested repeatedly and directly — strength and memory — and both have failed. Persisting at higher doses in pursuit of them only raises the androgenic burden.

  • Regulatory status: A dietary supplement in the United States since 1994, a prescription medicine in Canada, the United Kingdom, Australia and much of the European Union, and an approved drug only as the intravaginal insert for painful intercourse.

  • Doping status: The World Anti-Doping Agency prohibits DHEA at all times, in and out of competition, on its 2026 list. Tested athletes face sanction regardless of dose or intent.

  • Cost and access: Inexpensive over the counter — a year at 25 mg costs roughly $20 to $280. The prescription vaginal insert costs far more than generic vaginal estrogen, a payer incentive that can structurally bias formularies, guideline wording and which comparisons get funded.

Interaction with Foundational Habits

  • Sleep: Direct and bidirectional. DHEA’s excitatory receptor action can fragment sleep when taken late, while poor sleep raises cortisol and suppresses the adrenal androgen output being replaced. Practical consequence: morning dosing, with new-onset insomnia read as a sign the dose is too high rather than a separate problem.

  • Nutrition: Indirect. A high-isoflavone soy intake lowered circulating DHEA-S in a randomized crossover trial, so large swings in soy consumption can confound both the effect and the test result. Absorption of this poorly soluble steroid also improves when the capsule is taken with a fat-containing meal rather than on an empty stomach.

  • Exercise: Potentiating on hormones, neutral on outcomes. Resistance training raises endogenous DHEA and testosterone acutely, so the two can push levels above target together. However, a trial combining DHEA with endurance and resistance training in postmenopausal women found no added benefit over training alone.

  • Stress management: Direct and antagonistic. Chronic stress raises cortisol while suppressing DHEA, and a meta-analysis found DHEA supplementation lowers circulating cortisol, shifting the ratio between the two. Practical consequence: both are measured together, since a low DHEA-S driven by ongoing stress may respond to load reduction rather than to a hormone.

Monitoring Protocol & Defining Success

Baseline testing establishes whether a deficit exists at all and where the conversion will run. Before starting, a morning fasting draw captures DHEA-S, total and free testosterone, estradiol, a full lipid panel, fasting glucose, liver enzymes and a complete blood count; men over 40 add prostate-specific antigen. Ongoing monitoring follows a fixed cadence: repeat DHEA-S, sex hormones and lipids at 6–8 weeks, again at 3 months, then every 6–12 months once the dose is stable. Prostate-specific antigen is repeated annually in men. Success is not a number on its own but the combination of a DHEA-S value restored into the youthful range, sex hormones still inside their reference ranges, an unchanged protective cholesterol fraction, and a subjective improvement the person would notice without being told they were treated.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
DHEA-S Women 275–400 µg/dL; men 350–500 µg/dL Confirms a genuine deficit and prevents overshoot Fasting not required; drawn 12–24 h after the last dose. Conventional age-adjusted ranges fall below 100 µg/dL after 70, which is why they miss the deficit
Total and free testosterone Women 30–50 ng/dL total; men 500–800 ng/dL total The main conversion product in women Drawn before 10:00 and paired with SHBG (sex hormone-binding globulin, the carrier protein for sex hormones), which is needed to interpret the free fraction. Conventional laboratory ranges are far wider — roughly 265–915 ng/dL in men and 8–60 ng/dL in women — so a value inside them can still sit well below or above these targets
Estradiol Men 20–30 pg/mL; postmenopausal women below 30 pg/mL The main conversion product in men Requires an ultrasensitive assay at male concentrations; standard assays are unreliable below 30 pg/mL. The conventional male reference range runs to roughly 10–40 pg/mL, wide enough that a value inside it can still sit above the functional ceiling
HDL cholesterol Above 50 mg/dL in women, above 45 mg/dL in men The one lipid consistently lowered by oral DHEA 9–12 h fast. The conventional male floor is 40 mg/dL, below the functional target. Rechecked at 3 months because the fall appears early and then plateaus
Fasting glucose and HbA1c Glucose 75–85 mg/dL; HbA1c 4.8–5.3% Detects the disputed effect on glucose handling HbA1c is glycated hemoglobin, a three-month average of blood sugar; the conventional cut-offs of 5.7% and a fasting glucose below 100 mg/dL are far looser than the functional targets
PSA (men over 40) Below 1.0 ng/mL at 40–50, below 2.0 ng/mL thereafter, rising less than 0.35 ng/mL per year DHEA raises the androgens that drive prostate tissue PSA is prostate-specific antigen, a blood marker of prostate activity. The conventional cut-off of 4.0 ng/mL is far looser than these functional targets. Ejaculation and cycling within 48 h of the draw distort the result
ALT and AST Below 25 U/L in women, below 30 U/L in men Screens for hepatic strain ALT and AST are alanine and aspartate aminotransferase, enzymes released by stressed liver cells. Conventional laboratory upper limits run to roughly 40–45 U/L, well above these targets. Pooled trials found no change, so a rise points elsewhere
Hematocrit 38–46% in women, 40–50% in men Androgens can thicken the blood Taken from the same draw as the complete blood count; more relevant above 50 mg daily

Qualitative markers worth tracking alongside the laboratory values:

  • Morning energy and the point in the day at which fatigue arrives
  • Mood stability, irritability and motivation, rated weekly rather than daily
  • Sleep onset latency and night-time waking, which flag an excessive or mistimed dose
  • Libido and sexual satisfaction, the endpoint with the most consistent trial support
  • Skin oiliness, acne and unwanted hair growth, the earliest sign of androgen excess
  • Skin hydration and texture, which the one-year trial reported improving in women
  • Recovery from training sessions and perceived exertion at a fixed workload

Emerging Research

  • Thymus regeneration extension trial: NCT04375657 is a Phase 2 trial in 85 participants run by Intervene Immune, testing DHEA with growth hormone and metformin against epigenetic age, thymic regeneration and safety. Its design still does not isolate DHEA’s own contribution.

  • Head-to-head against vaginal estrogen: NCT07574216, the University of Arizona VEDA study, will randomise 324 women to vaginal DHEA or estradiol for genitourinary symptoms — the first comparison capable of showing DHEA is no better than a far cheaper generic.

  • Safety in breast cancer survivors: NCT06611514 is a Phase 3 trial in 95 postmenopausal women with prior breast cancer, testing whether intravaginal prasterone relieves genitourinary symptoms without measurable systemic hormone exposure in exactly the group currently excluded.

  • Anti-inflammatory extension beyond hormones: NCT07179952, a Phase 2 study of slow-release DHEA in 30 people with asthma at Indiana University, tests the immune actions described in narrative reviews using asthma-control scores as the endpoint.

  • Genetic causal inference on bone: Quester et al., 2022 used genetic variants as a natural experiment and reported that endogenous DHEA-S is causally linked to lumbar spine bone density and forearm fractures in women, strengthening the bone claim independently of supplementation trials.

  • Cognition looks closed rather than open: Sultana et al., 2023 reviewed four randomized trials of 50 mg daily in postmenopausal women and found no cognitive benefit, which argues against further trials in this domain and weakens the longevity case.

Conclusion

DHEA is a hormone the adrenal glands make in quantity in early adulthood and in steadily smaller amounts thereafter. The body converts it inside tissues into the male and female sex hormones, where most of its effects arise.

The evidence divides by who is taking it and how. Where the adrenal glands genuinely cannot make the hormone, replacement restores well-being, mood and sexual interest; where it is placed directly in vaginal tissue, it reliably relieves dryness and pain after menopause; and it modestly lifts self-rated health in a disease where the immune system attacks the body’s own tissues. In healthy older adults with intact adrenal glands, swallowed capsules have repeatedly failed to improve strength, physical function, memory or general well-being. Lower depression scores come from pooled trials whose authors rated their certainty as very low; the modest bone density gain in women and the softer arteries rest on single trials.

The drawbacks are predictable rather than dramatic: acne and unwanted hair growth, a fall in the protective cholesterol fraction in women, and hormone levels that drift when nobody is measuring them. The worry about hormone-driven cancers rests on cell work and on people’s own hormone levels, not on anyone taking it.

Two financial interests shape this literature. The company that developed the prescription vaginal product funded most of the trials supporting it, and a supplement seller that has long promoted it also publishes much of the popular writing. Neither invalidates the findings, but both sit behind much of it.

Top - Benefits - Risks - Protocol